Last reviewed · How we verify
Darbepoetin
Darbepoetin is a Small molecule drug developed by NICHD Neonatal Research Network. It is currently FDA-approved for Anemia due to and following chemotherapy, Anemia of renal disease. Also known as: Darbe, EPO.
Darbepoetin alfa is a protein-based erythropoietin receptor agonist used to treat anemia associated with chronic kidney disease and other conditions. It has a 3-fold longer serum half-life compared to epoetin alpha and epoetin beta, allowing for less frequent dosing.
At a glance
| Generic name | Darbepoetin |
|---|---|
| Also known as | Darbe, EPO |
| Sponsor | NICHD Neonatal Research Network |
| Target | Erythropoietin receptor |
| Modality | Small molecule |
| Therapeutic area | Hematology |
| Phase | FDA-approved |
Approved indications
- Anemia due to and following chemotherapy
- Anemia of renal disease
Common side effects
- Hypertension
- Injection site pain
- Rash
- Convulsions
Serious adverse events
- Hypertension
- Convulsions
- Cerebrovascular disorders
- Thromboembolic adverse reactions
Key clinical trials
- Luspatercept + Darbepoetin in MDS (PHASE2)
- Vafseo Outcomes In-Center Experience (PHASE3)
- Choices About Genetic Testing And Learning Your Risk With Smart Technology (NA)
- Darbe Plus IV Iron to Decrease Transfusions While Maintaining Iron Sufficiency in Preterm Infants (PHASE2)
- Efficacy and Safety Study to Evaluate MT-6548 in Non-dialysis Subjects With Anemia Associated With Chronic Kidney Disease in Japan (PHASE3)
- Efficacy and Safety Study to Evaluate MT-6548 in Hemodialysis Subjects Currently Receiving ESAs With Anemia Associated With Chronic Kidney Disease in Japan (PHASE3)
- A Study to Evaluate Efficacy and Safety of QLG1218(Daprodustat) in Chinese Hemodialysis (HD)-Dependent Subjects With Anemia Associated With Chronic Kidney Disease (CKD) (PHASE3)
- Darbepoetin in Patients Candidates for Liver Transplant. (EPO-LT Trial) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Darbepoetin CI brief — competitive landscape report
- Darbepoetin updates RSS · CI watch RSS
- NICHD Neonatal Research Network portfolio CI
Frequently asked questions about Darbepoetin
What is Darbepoetin?
What is Darbepoetin used for?
Who makes Darbepoetin?
Is Darbepoetin also known as anything else?
What development phase is Darbepoetin in?
What are the side effects of Darbepoetin?
What does Darbepoetin target?
Related
- Target: All drugs targeting Erythropoietin receptor
- Manufacturer: NICHD Neonatal Research Network — full pipeline
- Therapeutic area: All drugs in Hematology
- Indication: Drugs for Anemia due to and following chemotherapy
- Indication: Drugs for Anemia of renal disease
- Also known as: Darbe, EPO
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing